Cargando…

The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine

Mitochondrial processes may play a role in the pathophysiology of migraine. Serum levels of two biomarkers, Fibroblast-growth-factor 21 (FGF-21) and Growth-differentiation-factor 15 (GDF-15), are typically elevated in patients with mitochondrial disorders. The study investigated whether the presence...

Descripción completa

Detalles Bibliográficos
Autores principales: Burow, Philipp, Haselier, Marc, Naegel, Steffen, Scholle, Leila Motlagh, Gaul, Charly, Kraya, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471677/
https://www.ncbi.nlm.nih.gov/pubmed/34572118
http://dx.doi.org/10.3390/cells10092471
_version_ 1784574529531543552
author Burow, Philipp
Haselier, Marc
Naegel, Steffen
Scholle, Leila Motlagh
Gaul, Charly
Kraya, Torsten
author_facet Burow, Philipp
Haselier, Marc
Naegel, Steffen
Scholle, Leila Motlagh
Gaul, Charly
Kraya, Torsten
author_sort Burow, Philipp
collection PubMed
description Mitochondrial processes may play a role in the pathophysiology of migraine. Serum levels of two biomarkers, Fibroblast-growth-factor 21 (FGF-21) and Growth-differentiation-factor 15 (GDF-15), are typically elevated in patients with mitochondrial disorders. The study investigated whether the presence of migraine may influence FGF-21 and GDF-15 serum levels considering vascular and metabolic disorders as possible confounders. A cross-sectional study in two headache centers was conducted analyzing GDF-15 and FGF-21 serum concentration in 230 patients with episodic and chronic migraine compared to a control group. Key clinical features of headache were evaluated, as well as health-related life quality, anxiety and depression using SF-12 and HADS-questionnaires. Elevated GDF-15 values were detected in the migraine group compared to the control group (506.65 ± 275.87 pg/mL vs. 403.34 ± 173.29 pg/mL, p < 0.001, Mann–Whitney U test). A strong correlation between increasing age and higher GDF-15 levels was identified (p < 0.001, 95%-CI elevation of GDF-15 per year 5.246–10.850 pg/mL, multiple linear regression). Mean age was different between the groups, and this represents a confounding factor of the measurements. FGF-21 levels did not differ between migraine patients and controls (p = 0.635, Mann–Whitney U test) but were significantly influenced by increasing BMI (p = 0.030, multiple linear regression). Neither biomarker showed correlation with headache frequency. Higher FGF-21 levels were associated with a higher mean intensity of headache attacks, reduced health-related life quality and anxiety. When confounding factors were considered, increased serum levels of FGF-21 and GDF-15 were not detected in migraine patients. However, the results show an age-dependence of GDF-15 in migraine patients, and this should be considered in future studies. Similar findings apply to the relationship between FGF-21 and BMI. Previous studies that did not adjust for these factors should be interpreted with caution.
format Online
Article
Text
id pubmed-8471677
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84716772021-09-28 The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine Burow, Philipp Haselier, Marc Naegel, Steffen Scholle, Leila Motlagh Gaul, Charly Kraya, Torsten Cells Article Mitochondrial processes may play a role in the pathophysiology of migraine. Serum levels of two biomarkers, Fibroblast-growth-factor 21 (FGF-21) and Growth-differentiation-factor 15 (GDF-15), are typically elevated in patients with mitochondrial disorders. The study investigated whether the presence of migraine may influence FGF-21 and GDF-15 serum levels considering vascular and metabolic disorders as possible confounders. A cross-sectional study in two headache centers was conducted analyzing GDF-15 and FGF-21 serum concentration in 230 patients with episodic and chronic migraine compared to a control group. Key clinical features of headache were evaluated, as well as health-related life quality, anxiety and depression using SF-12 and HADS-questionnaires. Elevated GDF-15 values were detected in the migraine group compared to the control group (506.65 ± 275.87 pg/mL vs. 403.34 ± 173.29 pg/mL, p < 0.001, Mann–Whitney U test). A strong correlation between increasing age and higher GDF-15 levels was identified (p < 0.001, 95%-CI elevation of GDF-15 per year 5.246–10.850 pg/mL, multiple linear regression). Mean age was different between the groups, and this represents a confounding factor of the measurements. FGF-21 levels did not differ between migraine patients and controls (p = 0.635, Mann–Whitney U test) but were significantly influenced by increasing BMI (p = 0.030, multiple linear regression). Neither biomarker showed correlation with headache frequency. Higher FGF-21 levels were associated with a higher mean intensity of headache attacks, reduced health-related life quality and anxiety. When confounding factors were considered, increased serum levels of FGF-21 and GDF-15 were not detected in migraine patients. However, the results show an age-dependence of GDF-15 in migraine patients, and this should be considered in future studies. Similar findings apply to the relationship between FGF-21 and BMI. Previous studies that did not adjust for these factors should be interpreted with caution. MDPI 2021-09-18 /pmc/articles/PMC8471677/ /pubmed/34572118 http://dx.doi.org/10.3390/cells10092471 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Burow, Philipp
Haselier, Marc
Naegel, Steffen
Scholle, Leila Motlagh
Gaul, Charly
Kraya, Torsten
The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine
title The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine
title_full The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine
title_fullStr The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine
title_full_unstemmed The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine
title_short The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine
title_sort mitochondrial biomarkers fgf-21 and gdf-15 in patients with episodic and chronic migraine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471677/
https://www.ncbi.nlm.nih.gov/pubmed/34572118
http://dx.doi.org/10.3390/cells10092471
work_keys_str_mv AT burowphilipp themitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT haseliermarc themitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT naegelsteffen themitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT scholleleilamotlagh themitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT gaulcharly themitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT krayatorsten themitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT burowphilipp mitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT haseliermarc mitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT naegelsteffen mitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT scholleleilamotlagh mitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT gaulcharly mitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine
AT krayatorsten mitochondrialbiomarkersfgf21andgdf15inpatientswithepisodicandchronicmigraine